AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34714125
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care with mother's own milk (MOM)
Trial: 33783495
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment model)
Trial: 35413022
Drug: SARS-CoV-2 infection
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 infection (defined as COVID-19 clinical diagnosis or presence of SARS-CoV-2 IgG/IgA antibodies)
Trial: 36817782
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard antibiotic treatment)
Trial: 35225460
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml ONS twice a day
Trial: 32660299
Drug: Adjunctive low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive low-dose transdermal testosterone cream
Trial: 34298589
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin
Trial: 34019513
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of migraine headaches
Trial: 34758056
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) compound filling plus mesotherapy
Trial: 34758056
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin A (BTX-A) injection
Trial: 39001910
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC)
Trial: 36484803
Drug: Test methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test methotrexate tablet (2.5 mg) under fasting conditions
Trial: 32018065
Drug: Schema therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema therapy
Trial: 33852940
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg/day)
Trial: 35277166
Drug: 0.375% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% ropivacaine with 1 µg/kg dexmedetomidine in 20 ml for ESPB (Group E)
Trial: 36083489
Drug: Shugan Jieyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Jieyu capsule
Trial: 34674843
Drug: Intravenous piperacillin/tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous piperacillin/tazobactam for 24–48 h followed by 10 days of oral ciprofloxacin/metronidazole
Trial: 34388414
Drug: Intravenous thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiamine (200 mg every 12 hours for up to 14 doses)
Trial: 32799851
Drug: Single high-molecular-weight
RxNorm normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single high-molecular-weight hyaluronic acid (HMW-HA) injection (Arthromac)
Trial: 32799851
Drug: Triple low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple low-molecular-weight hyaluronic acid (LMW-HA) injections (Hyalgan)
Trial: 36035829
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (disposable ophthalmic single-port operation cloth)
Trial: 32580990
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered prednisolone 50 mg per day for up to 3 days, tapering to cessation over 10 days, in addition to guideline advice.
Trial: 33853550
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) at escalating doses starting from 6 Gy × 2 weekly fractions to a maximum of 6 Gy × 5 weekly fractions (dose level 4)
Trial: 33398094
Drug: Extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis (ECP) with steroids
Trial: 32950748
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg subcutaneous mirikizumab (maintenance therapy)
Trial: 39566051
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBOT)
Trial: 33836310
Drug: Thrice-weekly PRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly PRT plus impact exercise training
Trial: 33431967
Drug: 15% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% CO2 treatment
Trial: 33431967
Drug: High-CO2 concentration
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-CO2 concentration formulation
Trial: 33431967
Drug: NaOH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOH treatment (to correct medium acidification)
Trial: 33431967
Drug: Knockdown of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knockdown of H+-sensing G protein-coupled receptor 65
Trial: 33504555
Drug: Immunotherapy (dinutuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (dinutuximab + GM-CSF + IL2)
Trial: 35432566
Drug: ZuoJin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZuoJin Pill (ZJP)
Trial: 37141104
Drug: Water infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water infusion
Trial: 32844196
Drug: Levodopa therapy
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa therapy
Trial: 36341753
Drug: More intensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intensive treatment (systolic blood pressure target <120 mm Hg)
Trial: 36341753
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive treatment (systolic blood pressure target 140-180 mm Hg)
Trial: 38778383
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual
Trial: 35357058
Drug: Itopride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride (100 mg t.i.d.)
Trial: 33829609
Drug: Axitinib and
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib and carotuximab (TRC105) combination therapy
Trial: 33947608
Drug: Axitinib monotherapy
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib monotherapy
Trial: 33056965
Drug: Retinalamin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinalamin treatment course every 6 months
Trial: 36653090
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitor (evolocumab) 140 mg subcutaneous injection
Trial: 36653090
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitor (evolocumab)
Trial: 32992440
Drug: 0.9 g·kg·FFM−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g·kg·FFM−1 GLN (HIGH)
Trial: 32992440
Drug: 0.6 g·kg·FFM−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g·kg·FFM−1 GLN (MED)
Trial: 33710659
Drug: Video‐to‐home cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video‐to‐home cognitive‐behavioral therapy
Trial: 34003285
Drug: Cognitive Functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Functional Therapy+ (CFT+) with psychologist support and option of additional usual care
Trial: 36700035
Drug: Lacticaseibacillus rhamnosus
RxNorm normalized name: Lacticaseibacillus rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated at 1.0×10^10 colony-forming units once daily for 10 days
Trial: 34107173
Drug: Avelox 400
RxNorm normalized name: Avelox 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelox 400 mg
Trial: 35805767
Drug: Dental care,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental care, anticipatory guidance on oral health and dietary intake, motivational interviewing
Trial: 34657222
Drug: Ampreloxetine 5
RxNorm normalized name: Ampreloxetine
DrugBank: Ampreloxetine (DB15348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampreloxetine 5 mg and 10 mg
Trial: 34657222
Drug: Ampreloxetine (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampreloxetine (median dose 15 mg)
Trial: 34657222
Drug: Ampreloxetine (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampreloxetine (median dose 10 mg)
Trial: 33610175
Drug: Chloroprocaine HCl
RxNorm normalized name: chloroprocaine HCl
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroprocaine HCl 1% at 30 mg
Trial: 33610175
Drug: Chloroprocaine HCl
RxNorm normalized name: chloroprocaine HCl
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroprocaine HCl 1% at 40 mg
Trial: 33610175
Drug: Chloroprocaine HCl
RxNorm normalized name: chloroprocaine HCl
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroprocaine HCl 1% at 50 mg
Trial: 32662036
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate treatment duration less than 1 year
Trial: 34592778
Drug: Combination (Arsenicum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (Arsenicum album 30c, Bryonia alba 30c, Gelsemium sempervirens 30c, and Influenzinum 30c)
Trial: 32514196
Drug: Short treatment
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short treatment regimen (9 to 11 months)
Trial: 32514196
Drug: Long treatment
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long treatment regimen (20 to 22 months)
Trial: 35041809
Drug: 5% CBLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% CBLH (single injection)
Trial: 35041809
Drug: 10% CBLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% CBLH (single injection)
Trial: 35041809
Drug: 15% CBLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% CBLH (4-time injections)
Trial: 35041809
Drug: Phosphate buffered
RxNorm normalized name: Phosphate Buffered Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline (1 injection)
Trial: 33119068
Drug: 3AV (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3AV (10 μg)
Trial: 33119068
Drug: 1AV (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1AV (20 µg)
Trial: 35962934
Drug: Acid-reducing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-reducing agents (ARAs)
Trial: 34098984
Drug: Dihydroartemisinin-piperaquine, full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine, full course delivered by trained village health workers to all residents of compounds with reported clinical cases.
Trial: 32895281
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (target Hb levels of 70-90 g/L)
Trial: 35481441
Drug: Dietary 25-hydroxyvitamin
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary 25-hydroxyvitamin D3 at 4.9 µg/kg
Trial: 35481441
Drug: Dietary 25-hydroxyvitamin
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary 25-hydroxyvitamin D3 at 8.4 µg/kg
Trial: 35481441
Drug: Dietary 25-hydroxyvitamin
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary 25-hydroxyvitamin D3 at approximately 5.0 µg/kg
Trial: 37094892
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy
Trial: 35347400
Drug: Immediate spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate spa therapy
Trial: 35347400
Drug: Usual treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatments (Control)
Trial: 32534949
Drug: Standard calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard calorie administration based on predictive equations (20-25 kcal/kg ideal body weight/day)
Trial: 36278294
Drug: TS-P1 45
RxNorm normalized name: ALT-P1
DrugBank: ALT-P1 (DB18485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-P1 45 mg
Trial: 36278294
Drug: CR-033P 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR-033P 90 mg
Trial: 36278294
Drug: CR-043P 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR-043P 90 mg
Trial: 34973935
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH administered at 20:00 h
Trial: 34973935
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist administered at 08:00 h
Trial: 32940642
Drug: 0.1 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/L of α-MSH treatment
Trial: 36468983
Drug: SNRI-Duloxetine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNRI-Duloxetine therapy at a dose of 60 mg per day for 8 weeks
Trial: 36468983
Drug: Trimebutine therapy
RxNorm normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine therapy at a dose of 600 mg per day
Trial: 34087225
Drug: COSMOS intervention
RxNorm normalized name: Cosmos sulphureus flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COSMOS intervention (multicomponent intervention including staff training in communication, pain treatment, medication review, organization of activities, and safety) for 4 months
Trial: 37414137
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy
Trial: 37409838
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg kg ‐1 bolus followed by 4 mg kg ‐1 h ‐1 infusion)
Trial: 37409838
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 µg kg ‐1 followed by 2 µg kg ‐1 h‐1 infusion)
Trial: 35168636
Drug: Date palm
RxNorm normalized name: date palm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Date palm capsule
Trial: 32976523
Drug: L-carnitine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine infusion (28mg/kg) with Intralipid (20%, 90mL/h)
Trial: 35640636
Drug: Ad26.ZEBOV, MVA-BN-Filo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
Trial: 36464853
Drug: Lenvatinib 18
RxNorm normalized name: lenvatinib 18 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 18 mg/day
Trial: 32403115
Drug: Immediate iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate iron therapy
Trial: 32403115
Drug: Delayed iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed iron therapy (28-day delay)
Trial: 33992100
Drug: Spinal manual
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manual therapy
Trial: 35470195
Drug: Corticosteroid nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid nerve root injections
Trial: 35226756
Drug: solution-focused psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution-focused psychotherapy (n=97)
Trial: 33607803
Drug: therapy of
RxNorm normalized name: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy of 'combination 3 methods progression'
Trial: 35451636
Drug: Forced diuresis
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced diuresis using furosemide 1 mg/kg (GII)
Trial: 33175623
Drug: Eosin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosin 2% solution
Trial: 35477616
Drug: REL-1017 25
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 25 mg
Trial: 35477616
Drug: REL-1017 50
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 50 mg
Trial: 35145043
Drug: 14-day bismuth-based
RxNorm normalized name: bismuth subcitrate 14 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day bismuth-based quadruple therapy (n=102)
Trial: 35130447
Drug: Pre-clinical screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-clinical screening of drugs
Trial: 33051255
Drug: Low-dose SCS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SCS (initial dose ≤ 40 mg prednisone equivalent/d)
Trial: 33051255
Drug: Medium-dose SCS
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose SCS (initial dose = 40-100 mg prednisone equivalent/d)
Trial: 33154086
Drug: Remote Directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Directly Observed Therapy (R‐DOT)
Trial: 34340097
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg rectal, administered twice within the same day, starting at twelve hours after triggering)
Trial: 35763658
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg
Trial: 35961468
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT–I)
Trial: 32988690
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard vaccine education)
Trial: 35281612
Drug: High-energy shockwave
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy shockwave therapy (ESWT)
Trial: 39487326
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% monotherapy
Trial: 36150356
Drug: PDMP alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDMP alert for high dose
Trial: 32415846
Drug: Sertraline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (400 mg/day for 8 weeks, then tapered)
Trial: 32825982
Drug: Resistance Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance Training with Curcumin Supplement (RTC)
Trial: 32825982
Drug: Curcumin Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin Supplement (C)
Trial: 37626303
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline infusion)
Trial: 33032908
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg for 80 days
Trial: 33896706
Drug: Smartphone-based cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based cardiovascular risk reduction program using the 'BreastMate' application as an adjunct to standard care.
Trial: 37159200
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg)
Trial: 34324880
Drug: Enteral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral iron supplementation (mean 4.8 mg/kg/d in Epo group, 3.6 mg/kg/d in placebo group) at 60 days
Trial: 34324880
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean 3.6 mg/kg/d) at 60 days
Trial: 34324880
Drug: Epo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epo (mean 4.8 mg/kg/d) at 60 days
Trial: 34324880
Drug: Iron dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dose at 90 days
Trial: 33298149
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparins at 50 IU anti-Xa/kg twice daily or 75 IU anti-Xa twice daily in combination with aprotinin
Trial: 36214614
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) treatment
Trial: 35707984
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure Therapy (CPAP)
Trial: 35707984
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula Therapy (HFNC)